| 巫海龙,谢嘉文,李向宇,顾 莹,吴 唏.加味黄连解毒汤联合利拉鲁肽对初发2型糖尿病肥胖患者糖脂代谢、炎症反应及胰岛功能的影响[J].,2020,(19):3663-3667 |
| 加味黄连解毒汤联合利拉鲁肽对初发2型糖尿病肥胖患者糖脂代谢、炎症反应及胰岛功能的影响 |
| Effect of Jiawei Huanglianjiedu Decoction Combined with Liraglutide on Glucolipid Metabolism, Inflammatory Response and Islet Function of Obesity Patients with Newly Diagnosed Type 2 Diabetes Mellitus |
| 投稿时间：2019-12-28 修订日期：2020-01-23 |
| DOI：10.13241/j.cnki.pmb.2020.19.012 |
| 中文关键词: 2型糖尿病 肥胖 利拉鲁肽 加味黄连解毒汤 糖脂代谢 炎症反应 胰岛功能 |
| 英文关键词: Type 2 diabetes mellitus Obesity Liraglutide Jiawei huanglianjiedu decoction Glucolipid metabolism Inflammatory response Islet function |
| 基金项目:上海市科委科研基金资助项目（15JC1408131） |
|
| 摘要点击次数: 881 |
| 全文下载次数: 525 |
| 中文摘要: |
| 摘要 目的：探讨加味黄连解毒汤联合利拉鲁肽对初发2型糖尿病肥胖患者糖脂代谢、炎症反应及胰岛功能的影响。方法：选取2016年1月至2018年5月复旦大学附属华山医院北院收治的104例初发2型糖尿病肥胖患者，按照随机数字表法将患者分为对照组（n=52）和研究组（n=52）。对照组给予利拉鲁肽治疗，研究组给予加味黄连解毒汤联合利拉鲁肽治疗，两组均治疗3个月。比较两组治疗前、治疗3个月后体质量指数（BMI）、血糖指标[空腹血糖（FPG）、餐后2小时血糖（2hPG）、糖化血红蛋白（HbA1c）]、血脂指标[总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）]、炎症指标[C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）]及胰岛功能指标[胰岛素抵抗指数（HOMA-IR）、胰岛β细胞功能指数（HOMA-β）]，并记录两组治疗过程中不良反应发生情况。结果：治疗3个月后，两组的BMI、FPG、2hPG、HbA1c、HOMA-IR及血清TG、TC、LDL-C、CRP、TNF-α、IL-6水平均低于治疗前，HOMA-β及血清HDL-C水平均高于治疗前，且研究组BMI、FPG、2hPG、HbA1c、HOMA-IR及血清TG、TC、LDL-C、CRP、IL-6、TNF-α水平均较对照组降低，血清HDL-C水平及HOMA-β较对照组升高（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。结论：加味黄连解毒汤联合利拉鲁肽治疗初发2型糖尿病肥胖患者安全有效，能够减轻患者体重，改善血糖、血脂水平以及胰岛功能，减轻炎症反应。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effects of jiawei huanglianjiedu decoction combined with liraglutide on glucolipid metabolism, inflammatory response and islet function of obesity patients with newly diagnosed type 2 diabetes mellitus. Methods: 104 obesity patients with newly diagnosed type 2 diabetes mellitus who were treated in North Hospital of Huashan Hospital Affiliated to Fudan University from January 2016 to May 2018 were selected. Patients were divided into control group (n=52) and research group (n=52) according to random number table method. The control group was given liraglutide, and the research group was treated with jiawei huanglianjiedu decoction combined with liraglutide, the two groups were treated for 3 months. The body mass index (BMI), blood glucose index [fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c)], blood lipid index [total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)], inflammatory markers [C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6)] and islet function indicators [insulin resistance index (HOMA-IR), islet β cell function index (HOMA-β)] were compared between the two groups before treatment and 3 months after treatment.The occurrence of adverse reactions during the treatment was recorded. Results: 3 months after treatment, the BMI, FPG, 2hPG, HbA1c, HOMA-IR and serum levels of TG, TC, LDL-C, CRP, IL-6 and TNF-α in two groups were lower than those before treatment.serum levels of HDL-C and HOMA-β were higher than those before treatment. The BMI, FPG, 2hPG, HbA1c, HOMA-IR and serum levels of TG, TC, LDL-C, CRP, TNF-α and IL-6 in the research group were lower than those in the control group, the levels of HOMA-β and serum HDL-C were higher than those in control group(P<0.05). The incidence of adverse reactions in the research group was 13.46% (7/52), the incidence of adverse reactions in the control group was 5.77%(3/52). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Jiawei huanglian jiedu decoction combined with liraglutide is safe and effective in the treatment of obese patients with newly diagnosed type 2 diabetes mellitus. It can reduce the weight of patients, improve blood sugar, blood lipid levels and pancreatic islet function, and reduce inflammation. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
